Bulk Manufacturer of Controlled Substances Application: Siegfried USA, LLC, 32905-32906 [2018-15138]

Download as PDF 32905 Federal Register / Vol. 83, No. 136 / Monday, July 16, 2018 / Notices Transboundary Hydrocarbon Reservoirs in the Gulf of Mexico. These eight stipulations will be added as lease terms where applicable and will be enforceable as part of the lease. Appendix B of the Gulf of Mexico OCS Oil and Gas Lease Sales: 2017–2022; Gulf of Mexico Lease Sales 249, 250, 251, 252, 253, 254, 256, 257, 259, and 261; Final Multisale Environmental Impact Statement provides a list and description of standard post-lease conditions of approval that may be required by BOEM or the Bureau of Safety and Environmental Enforcement as a result of plan and permit review processes for the Gulf of Mexico OCS Region. After careful consideration, BOEM has selected the preferred alternative (Alternative A) in the 2018 GOM Supplemental EIS for proposed Lease Sale 251. BOEM’s selection of the preferred alternative meets the purpose and need for the proposed action, as identified in the 2018 GOM Supplemental EIS, and provides for orderly resource development with protection of the human, marine, and coastal environments while also ensuring that the public receives an equitable return for these resources and that free-market competition is maintained. Authority: This Notice of Availability of a Record of Decision is published pursuant to the regulations (40 CFR part 1505) implementing the provisions of the National Environmental Policy Act of 1969, as amended (42 U.S.C. 4321 et seq.). Dated: July 11, 2018. Walter D. Cruickshank, Acting Director, Bureau of Ocean Energy Management. [FR Doc. 2018–15181 Filed 7–13–18; 8:45 am] BILLING CODE 4310–MR–P INTERNATIONAL TRADE COMMISSION [Investigation No. 731–TA–1374–1376 (Final)] Citric Acid and Certain Citrate Salts From Belgium, Colombia, and Thailand sradovich on DSK3GMQ082PROD with NOTICES Determination On the basis of the record 1 developed in the subject investigations, the United States International Trade Commission (‘‘Commission’’) determines, pursuant to the Tariff Act of 1930 (‘‘the Act’’), that an industry in the United States is materially injured by reason of imports 1 The record is defined in sec. 207.2(f) of the Commission’s Rules of Practice and Procedure (19 CFR 207.2(f)). VerDate Sep<11>2014 17:31 Jul 13, 2018 Jkt 244001 of citric acid and certain citrate salts from Belgium, Colombia, and Thailand that have been found by the U.S. Department of Commerce (‘‘Commerce’’) to be sold in the United States at less than fair value (‘‘LTFV’’).2 3 4 Background 2 Citric Acid and Certain Citrate Salts from Thailand: Affirmative Final Determination of Sales at Less Than Fair Value and Final Affirmative Determination of Critical Circumstances in Part, 82 FR 25998, June 5, 2018; Citric Acid and Certain Citrate Salts from Belgium: Affirmative Final Determination of Sales at Less Than Fair Value, 82 FR 26001, June 5, 2018; Citric Acid and Certain Citrate Salts from Colombia: Affirmative Final Determination of Sales at Less Than Fair Value and Final Negative Determination of Critical Circumstances, 82 FR 26002, June 5, 2018. 3 The Commission also finds that imports subject to Commerce’s affirmative critical circumstances determination are not likely to undermine seriously the remedial effect of the antidumping duty order on Thailand. 4 Commissioner Jason E. Kearns did not participate in these investigations. Frm 00074 By order of the Commission. Issued: July 10, 2018. Lisa Barton, Secretary to the Commission. [FR Doc. 2018–15067 Filed 7–13–18; 8:45 am] The Commission, pursuant to section 735(b) of the Act (19 U.S.C. 1673d(b)), instituted these investigations effective June 2, 2017, following receipt of a petition filed with the Commission and Commerce by Archer Daniels Midland Company, Decatur, Illinois; Cargill, Incorporated, Minneapolis, Minnesota; and Tate & Lyle Ingredients Americas, LLC, Hoffman Estates, Illinois. The Commission scheduled the final phase of the investigations following notification of a preliminary determination by Commerce that imports of citric acid and certain citrate salts from Belgium, Colombia, and Thailand were being sold at LTFV within the meaning of section 733(b) of the Act (19 U.S.C. 1673b(b)). Notice of the scheduling of the final phase of the Commission’s investigation and of a public hearing to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the Federal Register of February 2, 2018 (83 FR 4922). The hearing was held in Washington, DC, on May 14, 2018, and all persons who requested the opportunity were permitted to appear in person or by counsel. The Commission made these determinations pursuant to section 735(b) of the Act (19 U.S.C. 1673d(b)). It completed and filed its determinations in these investigations on July 10, 2018. The views of the Commission are contained in USITC Publication 4799 (July 2018), entitled Citric Acid and Certain Citrate Salts from Belgium, Colombia, and Thailand: PO 00000 Investigation Nos. 731–TA–1374–1376 (Final). Fmt 4703 Sfmt 4703 BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Bulk Manufacturer of Controlled Substances Application: Siegfried USA, LLC ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before September 14, 2018. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. DATES: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on November 2, 2017, Siegfried USA, LLC, 33 Industrial Park Rd., Pennsville, NJ 08070 applied to be registered as a bulk manufacturer for the basic classes of controlled substances: SUPPLEMENTARY INFORMATION: Controlled substance Gamma Hydroxybutyric Acid. Dihydromorphine .... Hydromorphinol ...... E:\FR\FM\16JYN1.SGM 16JYN1 Drug code Schedule 2010 I 9145 9301 I I 32906 Federal Register / Vol. 83, No. 136 / Monday, July 16, 2018 / Notices Controlled substance Drug code Schedule DEPARTMENT OF JUSTICE Drug Enforcement Administration Methylphenidate ..... Amobarbital ............ Pentobarbital .......... Secobarbital ............ Codeine .................. Oxycodone ............. Hydromorphone ...... Hydrocodone .......... Methadone .............. Methadone intermediate. Morphine ................. Oripavine ................ Thebaine ................. Opium tincture ........ Oxymorphone ......... 1724 2125 2270 2315 9050 9143 9150 9193 9250 9254 II II II II II II II II II II 9300 9330 9333 9630 9652 II II II II II [Docket No. DEA–392] Importer of Controlled Substances Application: Cerilliant Corporation ACTION: [FR Doc. 2018–15138 Filed 7–13–18; 8:45 am] BILLING CODE 4410–09–P Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 15, 2018. Such persons may also file a written request for a hearing on the application on or before August 15, 2018. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette DATES: The company plans to manufacture the listed controlled substances in bulk for sale to its customers. Dated: July 10, 2018. John J. Martin, Assistant Administrator. Notice of application. Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been delegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on June 12, 2018, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665 applied to be registered as an importer of the following basic classes of controlled substances: sradovich on DSK3GMQ082PROD with NOTICES Controlled substance Drug code 3-Fluoro-N-methylcathinone (3–FMC) ............................................................................................................................. Cathinone ........................................................................................................................................................................ Methcathinone ................................................................................................................................................................. 4-Fluoro-N-methylcathinone (4–FMC) ............................................................................................................................. Pentedrone (a-methylaminovalerophenone) ................................................................................................................... Mephedrone (4-Methyl-N-methylcathinone) .................................................................................................................... 4-Methyl-N-ethylcathinone (4–MEC) ............................................................................................................................... Naphyrone ....................................................................................................................................................................... N-Ethylamphetamine ....................................................................................................................................................... N,N-Dimethylamphetamine .............................................................................................................................................. Fenethylline ..................................................................................................................................................................... Methaqualone .................................................................................................................................................................. JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) .................................................................................................. SR–18 (Also known as RCS–8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ................................................ 5-Fluoro-UR-144 and XLR11 [1-(5-Fluoropentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone .................. AB–FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ..................... JWH–019 (1-Hexyl-3-(1-naphthoyl)indole) ...................................................................................................................... AB–PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) ......................................... THJ–2201 [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone ................................................................... AB–CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide ................. ADB–PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) ................................. APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide .............................................................. JWH–081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) .................................................................................................. SR–19 (Also known as RCS–4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole .................................................................... JWH–018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) .............................................................................. JWH–122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) ..................................................................................................... UR–144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone ................................................................. JWH–073 (1-Butyl-3-(1-naphthoyl)indole) ....................................................................................................................... JWH–200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) .......................................................................................... AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) ....................................................................................................... JWH–203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) ...................................................................................................... PB–22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) ................................................................................................. 5F–PB–22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) ............................................................................ Alpha-ethyltryptamine ...................................................................................................................................................... Ibogaine ........................................................................................................................................................................... CP–47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) ................................................................ CP–47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol) .......................................... VerDate Sep<11>2014 17:31 Jul 13, 2018 Jkt 244001 PO 00000 Frm 00075 Fmt 4703 Sfmt 4703 E:\FR\FM\16JYN1.SGM 16JYN1 1233 1235 1237 1238 1246 1248 1249 1258 1475 1480 1503 2565 6250 7008 7011 7012 7019 7023 7024 7031 7035 7048 7081 7104 7118 7122 7144 7173 7200 7201 7203 7222 7225 7249 7260 7297 7298 Schedule I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I

Agencies

[Federal Register Volume 83, Number 136 (Monday, July 16, 2018)]
[Notices]
[Pages 32905-32906]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-15138]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Bulk Manufacturer of Controlled Substances Application: Siegfried 
USA, LLC

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before September 14, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DRW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.33(a), this is notice that on 
November 2, 2017, Siegfried USA, LLC, 33 Industrial Park Rd., 
Pennsville, NJ 08070 applied to be registered as a bulk manufacturer 
for the basic classes of controlled substances:

------------------------------------------------------------------------
         Controlled substance           Drug code         Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid............        2010  I
Dihydromorphine......................        9145  I
Hydromorphinol.......................        9301  I

[[Page 32906]]

 
Methylphenidate......................        1724  II
Amobarbital..........................        2125  II
Pentobarbital........................        2270  II
Secobarbital.........................        2315  II
Codeine..............................        9050  II
Oxycodone............................        9143  II
Hydromorphone........................        9150  II
Hydrocodone..........................        9193  II
Methadone............................        9250  II
Methadone intermediate...............        9254  II
Morphine.............................        9300  II
Oripavine............................        9330  II
Thebaine.............................        9333  II
Opium tincture.......................        9630  II
Oxymorphone..........................        9652  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for sale to its customers.

    Dated: July 10, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-15138 Filed 7-13-18; 8:45 am]
BILLING CODE 4410-09-P